Last reviewed · How we verify
norelgestromin + ethinyl estradiol; mercilon — Competitive Intelligence Brief
phase 3
contraceptive
Women's Health
Small molecule
Live · refreshed every 30 min
Target snapshot
norelgestromin + ethinyl estradiol; mercilon (norelgestromin + ethinyl estradiol; mercilon) — Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Norelgestromin and ethinyl estradiol are used to prevent pregnancy by suppressing ovulation and altering cervical mucus and the uterine lining.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| norelgestromin + ethinyl estradiol; mercilon TARGET | norelgestromin + ethinyl estradiol; mercilon | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | phase 3 | contraceptive | ||
| Ethinyl Estradiol / Norgestimate Oral Tablet | Ethinyl Estradiol / Norgestimate Oral Tablet | University of Colorado, Denver | marketed | Oral contraceptive (combined estrogen-progestin) | Estrogen receptor and progesterone receptor | |
| desogestrel/ethinyl estradiol | desogestrel/ethinyl estradiol | Teva Branded Pharmaceutical Products R&D, Inc. | marketed | Combined oral contraceptive | Progesterone receptor, estrogen receptor | |
| Depo Provera | Depo Provera | University of Alabama at Birmingham | marketed | Progestin; long-acting reversible contraceptive | Progesterone receptor | |
| Estradiol+Drospirenone | Estradiol+Drospirenone | Brigham and Women's Hospital | marketed | Combined oral contraceptive | Estrogen receptors (ER-α, ER-β) and progesterone receptors (PR); mineralocorticoid receptor antagonism | |
| Ethinyl estradiol / dienogest | Ethinyl estradiol / dienogest | Helsinki University Central Hospital | marketed | Combined oral contraceptive | Estrogen receptor, progesterone receptor | |
| etonogestrel-releasing implant contraceptive | etonogestrel-releasing implant contraceptive | University of Sao Paulo | marketed | Progestin contraceptive | Progesterone receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (contraceptive class)
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 2 drugs in this class
- Ospedale Policlinico San Martino · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- norelgestromin + ethinyl estradiol; mercilon CI watch — RSS
- norelgestromin + ethinyl estradiol; mercilon CI watch — Atom
- norelgestromin + ethinyl estradiol; mercilon CI watch — JSON
- norelgestromin + ethinyl estradiol; mercilon alone — RSS
- Whole contraceptive class — RSS
Cite this brief
Drug Landscape (2026). norelgestromin + ethinyl estradiol; mercilon — Competitive Intelligence Brief. https://druglandscape.com/ci/norelgestromin-ethinyl-estradiol-mercilon. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab